• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    3/19/24 1:31:02 PM ET
    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • Ontrak (NASDAQ:OTRK) shares increased by 97.6% to $0.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.3 million.
    • Fusion Pharmaceuticals (NASDAQ:FUSN) stock moved upwards by 97.41% to $21.0. The company's market cap stands at $1.5 billion.
    • SCWorx (NASDAQ:WORX) stock rose 70.74% to $3.21. The market value of their outstanding shares is at $3.8 million.
    • Enliven Therapeutics (NASDAQ:ELVN) stock increased by 29.19% to $16.33. The company's market cap stands at $675.2 million. The company's, Q4 earnings came out 3 days ago.
    • Vincerx Pharma (NASDAQ:VINC) stock rose 28.31% to $6.3. The market value of their outstanding shares is at $134.6 million.
    • NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 26.9% to $2.5. The market value of their outstanding shares is at $54.7 million.

    Losers

    • Acutus Medical (NASDAQ:AFIB) stock declined by 26.5% to $0.19 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 million.
    • Seelos Therapeutics (NASDAQ:SEEL) stock fell 25.91% to $0.68. The market value of their outstanding shares is at $9.3 million.
    • Lantern Pharma (NASDAQ:LTRN) stock declined by 19.38% to $8.03. The company's market cap stands at $86.2 million. As per the news, the Q4 earnings report came out yesterday.
    • Eyenovia (NASDAQ:EYEN) stock fell 18.31% to $1.25. The company's market cap stands at $55.1 million. As per the news, the Q4 earnings report came out yesterday.
    • Genprex (NASDAQ:GNPX) stock decreased by 16.88% to $3.4. The market value of their outstanding shares is at $5.0 million.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) stock decreased by 15.84% to $2.18. The company's market cap stands at $30.0 million. As per the press release, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $AFIB
    $ELVN
    $EYEN

    CompanyDatePrice TargetRatingAnalyst
    Enliven Therapeutics Inc.
    $ELVN
    6/16/2025$37.00Buy
    Goldman
    Enliven Therapeutics Inc.
    $ELVN
    12/13/2024$42.00Buy
    BTIG Research
    Eyenovia Inc.
    $EYEN
    11/18/2024$12.00 → $2.00Buy → Neutral
    H.C. Wainwright
    Enliven Therapeutics Inc.
    $ELVN
    9/9/2024$37.00Buy
    H.C. Wainwright
    Enliven Therapeutics Inc.
    $ELVN
    6/11/2024$32.00Outperform
    Robert W. Baird
    Enliven Therapeutics Inc.
    $ELVN
    4/9/2024$34.00Buy
    Mizuho
    Fusion Pharmaceuticals Inc.
    $FUSN
    12/27/2023$12.00 → $15.00Outperform → Strong Buy
    Raymond James
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    More analyst ratings

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

    Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene TherapyREQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung CancerREQORSA Boosts Natural Killer (NK) Cell Antitumor Activity AUSTIN, Texas, March 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting being held April 17-22, 2026 in San Diego, California. The collaborators

    3/18/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

    SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ("AD/PD™ 2026"), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually. The presentations will highlight a new integrated analysis of patient-level data from two previously completed Phase 1 studies evaluating troculeucel in patients with

    3/10/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    6/2/25 12:11:05 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    5/7/25 4:05:15 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Scodari Joseph C bought $25,000 worth of shares (24,631 units at $1.01), increasing direct ownership by 800% to 27,708 units (SEC Form 4)

    4 - Acurx Pharmaceuticals, Inc. (0001736243) (Issuer)

    1/8/25 4:32:30 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Enliven Therapeutics with a new price target

    Goldman initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00

    6/16/25 7:46:51 AM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Enliven Therapeutics with a new price target

    BTIG Research initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $42.00

    12/13/24 7:38:47 AM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eyenovia downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Eyenovia from Buy to Neutral and set a new price target of $2.00 from $12.00 previously

    11/18/24 7:44:30 AM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Collins Helen Louise

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    3/19/26 5:50:52 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Enliven Therapeutics Inc.

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    3/11/26 5:32:25 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Hohl Benjamin sold $295,839 worth of shares (10,000 units at $29.58), decreasing direct ownership by 16% to 51,000 units (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    3/10/26 6:15:22 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    3/18/26 7:03:51 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Acurx Pharmaceuticals Inc.

    S-8 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/12/26 4:15:31 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Acurx Pharmaceuticals Inc.

    10-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer)

    3/12/26 4:06:12 PM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Leadership Updates

    Live Leadership Updates

    View All

    Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational catalysts throughout 2026Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029BOULDER, Colo., March 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year e

    3/3/26 4:05:00 PM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

    Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven's Board of Directors Building on positive data reported in 2025, Enliven continues to prepare for Phase 3 trial initiation in 2026 and the commercialization of ELVN-001 BOULDER, Colo., Jan. 7, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the appointment of Scott Garland to its Board of Directors and the planned resignation of Andrew Phillips, Ph.D., who has decided to step down, effec

    1/7/26 9:00:00 AM ET
    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                           Friday, March 13, 2026  Time:                     

    2/16/26 8:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and STK11/KEAP1 alterations. FDA Type C meeting completed, providing regulatory guidance and pathway clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone combination strategy. LP-300 pr

    11/13/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $AFIB
    $ELVN
    $EYEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care